Crescita Signs Exclusive Distribution Agreement with FILLMED

Crescita Therapeutics Inc. (TSX: CTX) and (OTC US: CRRTF) (“Crescita” or the “Company”), a commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that it has entered into a distribution agreement (the “Agreement”) with Laboratoires FILLMED (formerly Laboratoires Filorga Medical, “FILLMED”) for the exclusive distribution of the ART-FILLER® injectables range and New Cellular Treatment Factor® (“NCTF®”) in Canada. FILLMED is a French aesthetic medicine company with expertise in developing aesthetic and cosmetic anti-ageing treatment solutions using hyaluronic acid.

The partnership with FILLMED will allow Crescita to expand its product offering in the medical aesthetic field with the addition of the hyaluronic acid (“HA”) ART-Filler® injectables range and NCTF® 135 HA, a skin rejuvenation solution indicated primarily for the improvement of skin quality and fine lines and a global leader in its category.

“We are thrilled to have been selected by FILLMED, a highly-regarded global leader in the medical aesthetic space to launch and distribute their products in Canada,” commented Serge Verreault, Crescita’s President and CEO. “We are excited for the opportunity to expand our medical aesthetic portfolio in Canada and be the first to bring these high quality advanced HA serums and injectables to Canadian practitioners and consumers.”

“We are delighted to start this new partnership with Crescita Therapeutics in Canada. This is the opportunity for us to expand our activities into North America and offer our high quality French-made products to Canadian doctors,” commented Christophe Foucher, Fillmed’s Chief Executive Officer. “We hope to write, together with Crescita, a successful new chapter of aesthetic medicine thanks to this collaboration.”